Open AccessBevacizumab plus dacomitinib combination therapy for L858R ‐mutated metastatic lung adenocarcinoma: A report of two cases
Author(s) -
Teng ChiKang,
Chen ChiehLung,
Chen TingHan,
Cheng WenChien,
Tu ChihYen
Publication year - 2022
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14396
Subject(s) - medicine , bevacizumab , adenocarcinoma , lung cancer , epidermal growth factor receptor , oncology , targeted therapy , tyrosine kinase inhibitor , combination therapy , gefitinib , metastasis , brain metastasis , cancer research , chemotherapy , cancer
Dual inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor pathways for the treatment for EGFR ‐mutated, metastatic non‐small cell lung cancer is supported by previous randomized controlled trials. However, the use of second‐generation irreversible EGFR tyrosine kinase inhibitor (TKI) dacomitinib in combination with antiangiogenic therapy has not been reported in the literature. Here, we report the case of a 73‐year‐old man who presented with hemoptysis and dyspnea on exertion and was diagnosed with right upper lung adenocarcinoma with pleural metastasis and L858R mutation. The second case is of a 60‐year‐old woman who presented with low back pain and was diagnosed with right lower lung adenocarcinoma with bone metastasis and L858R mutation. Both patients underwent first‐line therapy with the TKI dacomitinib in combination with bevacizumab. The first patient showed a nearly complete response, and the second patient showed a partial response after the combination therapy and no severe side effects.